Zhihong Zeng

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

8h-index875citations21works7.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(9), RNA Interference and Gene Delivery(5), PI3K/AKT/mTOR signaling in cancer(5), CAR-T cell therapy research(5), Acute Lymphoblastic Leukemia research(4)

Publications21 total

Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixedlineage Leukemia and mutated nucleophosmin-1
Haematologica·2025· 1 citedOpen Access
BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism
Cell Death Discovery·2025· 5 citedOpen Access
BH3 Mimetics Augment Cytotoxic T Cell Killing of Acute Myeloid Leukemia via Mitochondrial Apoptotic Mechanism
2024Open Access
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
Blood Advances·2024· 18 citedOpen Access
Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation
Blood·2024Open Access
Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in <i>IDH1</i>-Mutated Myeloid Malignancies
Blood·2024· 1 citedOpen Access
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
The Lancet Haematology·2024· 17 citedOpen Access
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile
Blood Advances·2024· 19 citedOpen Access
Dual-Targeting CD33/CD123 NANOBODY ® T Cell Engager Targeting Leukemia Blasts and Stem/Progenitor Cells in Relapsed AML
Blood·2023· 1 cited
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
Journal of Clinical Oncology·2020· 56 cited
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
American Journal of Hematology·2016· 52 citedOpen Access
Rapamycin derivatives reduce mTORC2 signaling and inhibitAKT activation inAML
2016· 1 cited
Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia
Blood·2015· 4 cited
Tumor Suppressor Role for B55 alpha PP2A Isoform in AML
Clinical Lymphoma Myeloma & Leukemia·2015
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Clinical Cancer Research·2015· 67 citedOpen Access
Abstract 3659: The AKT inhibitor MK-2206 promotes apoptosis in acute myeloid leukemia cells
Cancer Research·2012
The PP2A Subunit B55α Suppresses Survival Signaling in Acute Myeloid Leukemia Cells
Blood·2011
A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation
Blood·2010· 3 cited
Patterns and Prognostic Impact of PI3K-AKT Pathway Activation, Regulation and Downstream Activity in AML Using Reverse Phase Proteins Arrays (RPPA).
Blood·2007· 1 cited
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Blood·2006· 342 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Marina Konopleva(19), Michael Andreeff(9), Farhad Ravandi(6), Elias Jabbour(5), Gautam Borthakur(5), Steven M. Kornblau(5), Naval Daver(4), Hagop M. Kantarjian(4), Courtney D. DiNardo(4), Karen Yee(3), Francis J. Giles(3), Qi Zhang(3), Peter P. Ruvolo(3), Vivian Ruvolo(3), Dos D. Sarbassov(2), Ismael Samudio(2), Mark F. Munsell(2), C. Ellen Jackson(2), David M. Sabatini(2), William G. Wierda(2)